Antipsychotics prescription in Czech social care residential care facilities for seniors – results of DEMDATA study
Authors:
Mgr. Michal Šteffl, Ph.D. 1; Mgr. Anna Beránková 2; DOC. MUDR. Iva Holmerová, PH.D. 2; Univ. Prof. Dr. Stefanie R. Auer 3
Authors place of work:
Fakulta tělesné výchovy a sportu UK, Praha
1; Centrum pro studium dlouhověkosti a dlouhodobé péče, Fakulta humanitních studií UK, Praha
2; Danube University Krems, Austria
3
Published in the journal:
Geriatrie a Gerontologie 2018, 7, č. 3: 106-109
Category:
Original Article/Study
Summary
The number of patients with dementia is rising quickly, due to the ageing population. There is currently cca 160 thousand people with dementia, three quarters of them living at their homes. The numbers of patients living in residential care social services facilities is also rising significantly. In spite of this and even though the volume of literature about dementia published in the recent years is increasing, there is still relatively little awareness of the health conditions and care conditions in patients at such facilities. There are few studies in Europe which provide quality data for planning care at long-term care facilities. Information about prevalence of dementia in Austrian and Czech is sporadic. The DEMDATA study gathers data on the health conditions and healthcare conditions in dementia patients living in retirement homes and nursing homes in the Czech Republic (and analogous studies were done in Austria). One of the aspects studied was pharmacotherapy. We are currently analysing and processing information from the DEMDATA study. In this article we focus on antipsychotics.
Keywords:
dementia – retirement home – special regimen care home – neuropsychiatric symptoms
Zdroje
1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia:meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294(15): 1934–1943.
2. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia:meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14(3): 191–210.
3. Mulsant BH, Gharabawi GM, Bossie CA, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry 2004; 65(12): 1708–1714.
4. Disease APAWGoAs, other D, Rabins PV, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. The American journal of psychiatry 2007; 164(12 Suppl): 5–56.
5. Auer S, Linsmayer E, Berankova A, et al. DEMDATA: The Austrian-Czech institutional long term care project – design and protocol of a two-centre cross sectional study. BMC health services research 2017; 17(1): 296.
6. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. The American journal of psychiatry 1982; 139(9): 1136–1139.
7. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer’s disease:phenomenology and treatment. J Clin Psychiatry 1987; 48 Suppl: 9–15.
8. Thompson Coon J, Abbott R, Rogers M, et al. Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review. J Am Med Dir Assoc 2014; 15(10): 706–718.
9. Child A, Clarke A, Fox C, Maidment I. A pharmacy led program to review anti-psychotic prescribing for people with dementia. BMC Psychiatry 2012; 12(1): 155.
10. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999–2007. Arch Gen Psychiatry 2011; 68(2): 190–197.
11. Karlsson S, Rahm Hallberg I, Midlov P, Fagerstrom C. Trends in treatment with antipsychotic medication in relation to national directives, in people with dementia – a review of the Swedish context. BMC Psychiatry 2017; 17(1): 251.
12. Gallini A, Andrieu S, Donohue JM, et al. Trends in use of antipsychotics in elderly patients with dementia:Impact of national safety warnings. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 2014; 24(1): 95–104.
13. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia:a population-based time-series analysis. CMAJ :Canadian Medical Association journal = journal de l’Association medicale canadienne 2008; 179(5): 438–446.
14. Guthrie B, Clark SA, McCowan C. The burden of psychotropic drug prescribingin people with dementia:a populationdatabase study. Age Ageing 2010; 39(5): 637–642.
Štítky
Geriatrics General practitioner for adults Orthopaedic prostheticsČlánok vyšiel v časopise
Geriatrics and Gerontology
2018 Číslo 3
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- The irreplaceable role of rehabilitation in geriatric patients at post-acute care centres.
- Needs of senior patients in hospital care – analysis of Czech literature review results.
- Neuropsychiatric symptoms of dementia and their management.
- Care integration – coordination barriers – aspects of integrated care – patients with complex needs – Czech Republic